IL201117A0 - 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS - Google Patents

3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Info

Publication number
IL201117A0
IL201117A0 IL201117A IL20111709A IL201117A0 IL 201117 A0 IL201117 A0 IL 201117A0 IL 201117 A IL201117 A IL 201117A IL 20111709 A IL20111709 A IL 20111709A IL 201117 A0 IL201117 A0 IL 201117A0
Authority
IL
Israel
Prior art keywords
hydroquinazolin
derivatives
coa desaturase
stearoyl coa
desaturase inhibitors
Prior art date
Application number
IL201117A
Other languages
English (en)
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of IL201117A0 publication Critical patent/IL201117A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL201117A 2007-04-11 2009-09-23 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS IL201117A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91122507P 2007-04-11 2007-04-11
PCT/US2008/004632 WO2008127615A1 (en) 2007-04-11 2008-04-10 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Publications (1)

Publication Number Publication Date
IL201117A0 true IL201117A0 (en) 2010-05-17

Family

ID=39709340

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201117A IL201117A0 (en) 2007-04-11 2009-09-23 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Country Status (12)

Country Link
US (1) US20080255161A1 (https=)
EP (1) EP2155695A1 (https=)
JP (1) JP2010523674A (https=)
KR (1) KR20100016421A (https=)
CN (1) CN101652353A (https=)
AU (1) AU2008239689A1 (https=)
BR (1) BRPI0809551A2 (https=)
CA (1) CA2683925A1 (https=)
IL (1) IL201117A0 (https=)
MX (1) MX2009010894A (https=)
RU (1) RU2009141596A (https=)
WO (1) WO2008127615A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522676A (zh) * 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2242367A4 (en) * 2008-01-08 2012-07-04 Univ Pennsylvania Rel inhibitors and methods of use thereof
US8088792B2 (en) * 2008-04-04 2012-01-03 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
CA2719362A1 (en) * 2008-04-04 2009-10-08 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
WO2010045374A1 (en) * 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
MX2014012991A (es) 2012-04-24 2015-08-14 Chugai Pharmaceutical Co Ltd Derivado de benzamida.
TW201348213A (zh) 2012-04-24 2013-12-01 Chugai Pharmaceutical Co Ltd 喹唑啉二酮衍生物
JP6307088B2 (ja) * 2013-10-23 2018-04-04 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CN114269756B (zh) * 2019-07-02 2024-05-14 效应疗法股份有限公司 抑制eif4e的4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN110903253B (zh) * 2019-12-13 2020-12-25 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物
IN202011027502A (https=) * 2020-06-29 2021-12-31 Council Scient Ind Res
EP4185380A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Quinazolinone hsd17b13 inhibitors and uses thereof
CN116670118B (zh) * 2020-11-13 2026-02-06 伊尼制药公司 二氯苯酚hsd17b13抑制剂及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS5920668B2 (ja) * 1975-10-03 1984-05-15 田辺製薬株式会社 キナゾリン誘導体の製法
JPS5920670B2 (ja) * 1976-04-10 1984-05-15 田辺製薬株式会社 キナゾリノン誘導体の製法
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
JP3488890B2 (ja) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
KR100423590B1 (ko) * 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
WO2000001389A1 (en) * 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003238157A1 (en) * 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
JP2006193426A (ja) * 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
US20070270589A1 (en) * 2003-11-28 2007-11-22 Mitsubishi Pharma Corporation Quinazoline Derivative and Process for Producing the Same
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
PT1830869E (pt) * 2004-12-24 2013-08-22 Spinifex Pharm Pty Ltd Método de tratamento ou profilaxia
CN101522676A (zh) * 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2008092231A1 (en) * 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS

Also Published As

Publication number Publication date
EP2155695A1 (en) 2010-02-24
KR20100016421A (ko) 2010-02-12
JP2010523674A (ja) 2010-07-15
MX2009010894A (es) 2009-10-26
BRPI0809551A2 (pt) 2014-09-16
WO2008127615A1 (en) 2008-10-23
US20080255161A1 (en) 2008-10-16
CA2683925A1 (en) 2008-10-23
CN101652353A (zh) 2010-02-17
RU2009141596A (ru) 2011-05-20
AU2008239689A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
IL201117A0 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
IL197828A0 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
BRPI0910987A2 (pt) derivados de triazolopiridinona para uso como inibidores de estearoil-coa dessaturase
GB0812031D0 (en) Thiazole derivatives
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
SI2297115T1 (sl) Dialkoksikinazolinski derivati kot inhibitorji kdr
ZA200807713B (en) Thiazolyldihydrocyclopentapyrazoles for use as PI3-kinase inhibitors
ZA201101236B (en) New 2-amidothiadiazole derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL208626A0 (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL213228A0 (en) Cutting fluid composition for wiresawing
GB0911703D0 (en) Additive for coating compounds and its use
ZA201102837B (en) Phosphodiestarase inhibitors
GB0911614D0 (en) Additive for coating compounds and its use
ZA200903979B (en) Acetylene derivatives as stearoyl CoA desaturase inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1141273A (en) 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
HK1160112A (en) 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
HK1139317A (en) Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
GB0714941D0 (en) Inhibitors